Skip to main content
Home hosted by UNOPS Stop TB Partnership
  • Who We Are
    • Stop TB Partnership
      • Our Journey
      • Action Plan
      • Work with us
    • The Secretariat
    • The Board
      • Board Members
      • Board Meetings
      • Board Committees
      • Board Delegations
        • Affected Communities Delegation to the Stop TB Partnership Board
        • Developing Country NGO Delegation to the Stop TB Partnership Board
        • Developed Country NGO Delegation to the Stop TB Partnership Board
      • Report of Decision Points
      • Board Affairs Documents
    • Stop TB Working Groups
      • Child and Adolescent TB
      • End TB Transmission Initiative
        • ETT Initiative Members
        • ETT Initiative Resources
        • ETT Initiative Events
        • ETT Initiative Newsletters
      • Global Drug-resistant TB Initiative
      • Global Laboratory Initiative (GLI)
      • New Diagnostics
        • Task Force on Biomarkers for TB point-of-care tests
        • Task Force on NGS and DST
        • Task Force on TBI and test of progression
        • Task Force on Community Engagement
        • About the NDWG
        • NDWG Team
        • New Diagnostics Working Group Resources
          • Guidelines & Policies
          • Meetings & Events
          • Publications
          • Scientific Articles
          • News
          • News Archive
          • Newsletters
          • Links
      • New TB Drugs
      • New TB Vaccines
      • Public-Private Mix (PPM) For TB Care and Prevention
      • TB/HIV Working Group
  • What we do
    • Advocate to #EndTB
      • Advocacy and Communications
      • World TB Day
      • UN High-Level Meeting on TB
        • UN High-Level Meeting on TB 2023
        • UN High Level Meeting on TB 2018
      • Global Plan to End TB
      • Step Up for TB: National TB Policies
      • Tuberculosis Research Funding Trends, 2005–2020
      • Hello Kitty
      • The G20
    • Prioritize people, human rights & gender
      • Fund TB communities & civil society
      • Community-Led Monitoring
      • Promote Human Rights in TB
      • Support Gender Equality in TB
      • End TB Stigma
      • Reach Key & Vulnerable Populations
      • Social Accountability & Governance
      • Empower TB Affected Communities & Civil Society
      • Strengthen national partnerships
      • Award those who care
    • Accelerate TB innovations
      • TB REACH
        • How TB REACH Works
        • The Team
        • TB REACH Impact
        • Catalyzing Diagnostic Use
        • Ground Up Innovation
        • Monitoring Success
        • Waves of funding
        • TB Reach publications
      • Re-imagining TB care
        • “Sandbox” Network
        • Mapping the Technology Landscape of National TB Programs
        • Virtual Innovation Spotlights
      • Accelerator for Impact (a4i)
      • Digital Health Technology Hub
        • AI-Powered Computer-Aided Detection (CAD) Software
        • Community-Led Monitoring Tools
        • Diagnostics Connectivity Solutions
        • Digital Adherence Technologies
        • Global DAT Task Force
      • The Introducing New Tools Project
    • Facilitate Access to TB Drugs & Diagnostics
      • Global Drug Facility (GDF)
        • Mission
        • Market & Partner Coordination
        • Buyers
        • Suppliers
        • New Tools
        • Technical Assistance
        • Products Catalog
    • Provide technical support and capacity building
  • Partner With Us
    • Why Become a Partner
    • How to become a Partner
    • The benefits of partnership
    • Our Partners
    • Joining Forces to #EndTB
      • Additional resources
  • Resources
    • World TB Day
    • Interactive TB data
      • Interactive Country Dashboard
      • Interactive Map Dashboard
      • Treatment Dashboard
    • Digital TB Assessment
    • GDF Resources
    • TB & COVID
    • Publications
    • Governance of TB programs
    • UNHLM Targets & Commitments
    • COMMUNITIES, RIGHTS AND GENDER
    • At A Glance
    • What is Tuberculosis?
  • News
    • News
    • Events
    • Newsletter
  • Donate
  1. Home
  2. Who We Are
  3. Stop TB Working Groups
  4. New Diagnostics
  5. New Diagnostics Working Group Resources
  6. New Diagnostics Working Group Scientific Articles

New Diagnostics Working Group Scientific Articles

  • How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?
    Qin ZZ, Pai M, Van Gemert W, Sahu S, Ghiasi M, Creswell J. Eur Respir J. 2014
  • Enhancing TB case detection: Experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR-TB cases for early rapid diagnosis of drug sensitive and drug resistant TB
    Raizada N, Sachdeva KS, Nair SA, Kulsange S, Gupta RS, Thakur R, Parmar M, Gray C, Ramachandran R, Vadera B, Ekka S, Dhawan S, Babre A, Ghedia M, Alavadi U, Dewan P, Khetrapal M, Khanna A, Boehme C, Paramsivan CN, PLoS ONE 9(8): e105346. doi:10.1371/journal.pone.0105346
  • Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
    Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Cochrane Database Syst Rev. 2014 Jan
  • The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs.
    Theron G, Peter J, Richardson M, Barnard M, Donegan S, Warren R, Steingart KR, Dheda K. Cochrane Database Syst Rev. 2014
  • Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study
    Miotto P, Cabibbe AM, Feuerriegel S, Casali N, Drobniewski F, Rodionova Y, Bakonyte D, Stakenas P, Pimkina E, Augustynowicz-Kopec E, Degano M, Ambrosi A, Hoffner S, Mansjo M, Werngren J, Rusch-Gerdes S, Niemann S, Cirillo DM. MBio. 2014
  • Genotypic susceptibility testing of Mycobacterium tuberculosis for Amikacin and Kanamycin resistance using a rapid Sloppy Molecular Beacon based assay identifies more cases of low level drug resistance than phenotypic Lowenstein-Jensen testing.
    Chakravorty S, Lee JS, Cho EJ, Roh SS, Smith LE, Lee J, Kim CT, Via LE, Cho SN, Barry CE 3rd, Alland D. J Clin Microbiol. 2014
  • The Combined Use of M. tuberculosis-specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis.
    Rozot V, Patrizia A, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, Lazor-Blanchet C, Ohmiti K, Goletti D, Bart PA, Hanekom W, Scriba TJ, Nicod L, Pantaleo G, Harari A. Clin Infect Dis. 2014

The Stop TB Partnership

Global Health Campus,
Chemin du Pommier 40,
1218 Le Grand-Saconnex, Geneva, Switzerland

Find us on Facebook Find us on Twitter Find us on Instagram Find us on LinkedIn

Useful links

  • Careers
  • Sitemap
  • FAQ
  • Terms of Use
  • Contact
  • Privacy Policy

Suscribe to stay informed

Sign up to learn more about TB and events.

© 2019 Stop TB Partnership - hosted by UNOPS
access